Teva Reports Positive Results of Multiple Sclerosis Study
Posted on: Friday, 11 April 2008, 12:00 CDT
Teva Pharmaceutical Industries has reported encouraging results from a three-year study evaluating relapsing-remitting multiple sclerosis patients who failed first-line monotherapy and switched treatments.
The results demonstrated that patients who switched from interferon beta (IFN beta) to Copaxone (glatiramer acetate injection) experienced a 77% reduction in annualized relapse rates (0.63 to 0.14). In addition, these patients did not progress significantly in their disability as measured by expanded disability status scale (EDSS).
The study evaluated the clinical efficacy of switching patients who responded inadequately to first-line immunomodulatory therapy. All patients who switched among the immunomodulatory treatments benefited in terms of relapse rate reduction, however, those who switched from IFN beta to Copaxone experienced no significant disability progression, while patient disability continued to increase in patients who switched from Copaxone to IFN beta or from one IFN beta to another IFN beta.
In addition, proportion of patients who did not experience a relapse over the entire three-year treatment period, increased from 16% to 68% following switch to Copaxone. Whereas the proportion of relapse-free patients switching from one IFN beta to another IFN beta remained similar before and after switch.
Adriana Carra, principal investigator of the study, said: "For patients switching from IFN beta to Glatiramer Acetate, the results obtained are consistent with those of previous studies demonstrating a robust reduction in mean annualized relapse rate and a stabilization of disease progression."
Source: Datamonitor
Related Articles
- Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients With Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
- New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Study Shows That High-Dose, High-Frequency Interferon Produces No Additional Benefit on Efficacy Compared to AVONEX(R) (Interferon Beta-1a) in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)
- Long-Term Study Shows COPAXONE(R) Significantly Slows Progression of Disability and Reduces Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
- Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients With Relapsed/Refractory Lymphoma Presented at ASCO
- BioCryst Initiates Pivotal Fodosine(TM) Phase IIb Clinical Trial in Patients With Relapsed/Refractory T-Lymphoblastic Leukemia/Lymphoma
- Phase II Study Demonstrates That ONTAK(R) Benefits Patients With Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma
- Novartis: FTY720 Phase II 12-Month Data Show Sustained Benefits and Good Tolerability in Patients With Relapsing Multiple Sclerosis
- Phase II Data Show Combination Biological Therapy With Galiximab and RITUXAN is Well-Tolerated and May Extend Event-Free Survival in Patients With Relapsed or Refractory, Follicular Lymphoma
- Abstracts Demonstrate That ONTAK May Benefit Patients With Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma and B-Cell Chronic Lymphocytic Leukemia
 |
 |
User Comments (0)
RSS Feeds